APO Research
Talk to an analyst

APO RESEARCH · REPORT

Daptomycin API

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Daptomycin API Market Outlook and Growth Opportunities 2026

2 January 2026192 pages

Choose your research edition.

Industry ResearchDaptomycin API Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Daptomycin API Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Daptomycin API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Daptomycin API Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Daptomycin API Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Daptomycin API market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Daptomycin API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Daptomycin API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Daptomycin API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Daptomycin API market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Daptomycin API market include Chongqing DaXin Pharmaceutical Co, Suzhou Pharmaceutical Technology Co, Livzon Group Fuzhou Fuxing Pharmaceutical Co, Huazhong Pharmaceutical Co, Xellia Pharmaceuticals, Tecoland Corporation, Rochem International Inc and Athos, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Daptomycin API market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Daptomycin API and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Daptomycin API sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Daptomycin API market size, projected growth trends, production technologies, key applications, and end-use industries.

Daptomycin API Segment by Company

Chongqing DaXin Pharmaceutical Co

Suzhou Pharmaceutical Technology Co

Livzon Group Fuzhou Fuxing Pharmaceutical Co

Huazhong Pharmaceutical Co

Xellia Pharmaceuticals

Tecoland Corporation

Rochem International Inc

Athos

Daptomycin API Segment by Type

0.99

0.98

Others

Daptomycin API Segment by Application

350mg/vial

500mg/vial

Others

Daptomycin API Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Daptomycin API status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Daptomycin API market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Daptomycin API significant trends, drivers, influence factors in global and regions.

6. To analyze Daptomycin API competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Daptomycin API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Daptomycin API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Daptomycin API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Daptomycin API market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Daptomycin API industry.

Chapter 3: Detailed analysis of Daptomycin API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Daptomycin API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Daptomycin API in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Daptomycin API Industry Trends Table 2. Daptomycin API Industry Drivers Table 3. Daptomycin API Industry Opportunities and Challenges Table 4. Daptomycin API Industry Restraints Table 5. Global Daptomycin API Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Daptomycin API Revenue Share by Company (2021-2026) Table 7. Global Daptomycin API Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Daptomycin API Sales Volume Share by Company (2021-2026) Table 9. Global Daptomycin API Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Daptomycin API Company Ranking, (2024-2026) & (USD Million) Table 11. Global Daptomycin API Key Company Manufacturing Base & Headquarters Table 12. Global Daptomycin API Company, Product Type & Application Table 13. Global Daptomycin API Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Daptomycin API by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 0.99 Table 18. Significant Companies of 0.98 Table 19. Significant Companies of Others Table 20. Global Daptomycin API Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 21. Global Daptomycin API Sales Volume by Type (2021-2026) & (Tons) Table 22. Global Daptomycin API Sales Volume by Type (2027-2032) & (Tons) Table 23. Global Daptomycin API Sales Volume Share by Type (2021-2026) Table 24. Global Daptomycin API Sales Volume Share by Type (2027-2032) Table 25. Global Daptomycin API Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Daptomycin API Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Daptomycin API Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Daptomycin API Sales Value Share by Type (2021-2026) Table 29. Global Daptomycin API Sales Value Share by Type (2027-2032) Table 30. Significant Companies of 350mg/vial Table 31. Significant Companies of 500mg/vial Table 32. Significant Companies of Others Table 33. Global Daptomycin API Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 34. Global Daptomycin API Sales Volume by Application (2021-2026) & (Tons) Table 35. Global Daptomycin API Sales Volume by Application (2027-2032) & (Tons) Table 36. Global Daptomycin API Sales Volume Share by Application (2021-2026) Table 37. Global Daptomycin API Sales Volume Share by Application (2027-2032) Table 38. Global Daptomycin API Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Daptomycin API Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Daptomycin API Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Daptomycin API Sales Value Share by Application (2021-2026) Table 42. Global Daptomycin API Sales Value Share by Application (2027-2032) Table 43. Global Daptomycin API Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 44. Global Daptomycin API Sales by Region (2021-2026) & (Tons) Table 45. Global Daptomycin API Sales Market Share by Region (2021-2026) Table 46. Global Daptomycin API Sales by Region (2027-2032) & (Tons) Table 47. Global Daptomycin API Sales Market Share by Region (2027-2032) Table 48. Global Daptomycin API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Daptomycin API Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Daptomycin API Sales Value Share by Region (2021-2026) Table 51. Global Daptomycin API Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Daptomycin API Sales Value Share by Region (2027-2032) Table 53. Global Daptomycin API Market Average Price (US$/Ton) by Region (2021-2026) Table 54. Global Daptomycin API Market Average Price (US$/Ton) by Region (2027-2032) Table 55. Global Daptomycin API Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 56. Global Daptomycin API Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Daptomycin API Sales by Country (2021-2026) & (Tons) Table 58. Global Daptomycin API Sales Market Share by Country (2021-2026) Table 59. Global Daptomycin API Sales by Country (2027-2032) & (Tons) Table 60. Global Daptomycin API Sales Market Share by Country (2027-2032) Table 61. Global Daptomycin API Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Daptomycin API Sales Value Market Share by Country (2021-2026) Table 63. Global Daptomycin API Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Daptomycin API Sales Value Market Share by Country (2027-2032) Table 65. Chongqing DaXin Pharmaceutical Co Company Information Table 66. Chongqing DaXin Pharmaceutical Co Business Overview Table 67. Chongqing DaXin Pharmaceutical Co Daptomycin API Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 68. Chongqing DaXin Pharmaceutical Co Daptomycin API Product Portfolio Table 69. Chongqing DaXin Pharmaceutical Co Recent Development Table 70. Suzhou Pharmaceutical Technology Co Company Information Table 71. Suzhou Pharmaceutical Technology Co Business Overview Table 72. Suzhou Pharmaceutical Technology Co Daptomycin API Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 73. Suzhou Pharmaceutical Technology Co Daptomycin API Product Portfolio Table 74. Suzhou Pharmaceutical Technology Co Recent Development Table 75. Livzon Group Fuzhou Fuxing Pharmaceutical Co Company Information Table 76. Livzon Group Fuzhou Fuxing Pharmaceutical Co Business Overview Table 77. Livzon Group Fuzhou Fuxing Pharmaceutical Co Daptomycin API Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 78. Livzon Group Fuzhou Fuxing Pharmaceutical Co Daptomycin API Product Portfolio Table 79. Livzon Group Fuzhou Fuxing Pharmaceutical Co Recent Development Table 80. Huazhong Pharmaceutical Co Company Information Table 81. Huazhong Pharmaceutical Co Business Overview Table 82. Huazhong Pharmaceutical Co Daptomycin API Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 83. Huazhong Pharmaceutical Co Daptomycin API Product Portfolio Table 84. Huazhong Pharmaceutical Co Recent Development Table 85. Xellia Pharmaceuticals Company Information Table 86. Xellia Pharmaceuticals Business Overview Table 87. Xellia Pharmaceuticals Daptomycin API Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 88. Xellia Pharmaceuticals Daptomycin API Product Portfolio Table 89. Xellia Pharmaceuticals Recent Development Table 90. Tecoland Corporation Company Information Table 91. Tecoland Corporation Business Overview Table 92. Tecoland Corporation Daptomycin API Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 93. Tecoland Corporation Daptomycin API Product Portfolio Table 94. Tecoland Corporation Recent Development Table 95. Rochem International Inc Company Information Table 96. Rochem International Inc Business Overview Table 97. Rochem International Inc Daptomycin API Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 98. Rochem International Inc Daptomycin API Product Portfolio Table 99. Rochem International Inc Recent Development Table 100. Athos Company Information Table 101. Athos Business Overview Table 102. Athos Daptomycin API Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 103. Athos Daptomycin API Product Portfolio Table 104. Athos Recent Development Table 105. Key Raw Materials Table 106. Raw Materials Key Suppliers Table 107. Daptomycin API Distributors List Table 108. Daptomycin API Customers List Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Daptomycin API Product Image Figure 2. Global Daptomycin API Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Daptomycin API Sales Value (2021-2032) & (US$ Million) Figure 4. Global Daptomycin API Sales (2021-2032) & (Tons) Figure 5. Global Daptomycin API Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Daptomycin API Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 0.99 Image Figure 10. 0.98 Image Figure 11. Others Image Figure 12. Global Daptomycin API Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 13. Global Daptomycin API Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Daptomycin API Sales Volume Share by Type (2021-2032) Figure 15. Global Daptomycin API Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Daptomycin API Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Daptomycin API Sales Value Share by Type (2021-2032) Figure 18. 350mg/vial Image Figure 19. 500mg/vial Image Figure 20. Others Image Figure 21. Global Daptomycin API Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 22. Global Daptomycin API Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Daptomycin API Sales Volume Share by Application (2021-2032) Figure 24. Global Daptomycin API Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Daptomycin API Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Daptomycin API Sales Value Share by Application (2021-2032) Figure 27. Global Daptomycin API Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 28. Global Daptomycin API Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Daptomycin API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Daptomycin API Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Daptomycin API Sales Value (2021-2032) & (US$ Million) Figure 32. North America Daptomycin API Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Daptomycin API Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Daptomycin API Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Daptomycin API Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Daptomycin API Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Daptomycin API Sales Value (2021-2032) & (US$ Million) Figure 38. South America Daptomycin API Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Daptomycin API Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Daptomycin API Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Daptomycin API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Daptomycin API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Daptomycin API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Daptomycin API Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Daptomycin API Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 0.99
  • 0.98
  • Others
Applications
  • 350mg/vial
  • 500mg/vial
  • Others
Companies covered
  • Chongqing DaXin Pharmaceutical Co
  • Suzhou Pharmaceutical Technology Co
  • Livzon Group Fuzhou Fuxing Pharmaceutical Co
  • Huazhong Pharmaceutical Co
  • Xellia Pharmaceuticals
  • Tecoland Corporation
  • Rochem International Inc
  • Athos

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Daptomycin API Sales Value (2021-2032)
  4. 1.2.2 Global Daptomycin API Sales Volume (2021-2032)
  5. 1.2.3 Global Daptomycin API Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Daptomycin API Market Dynamics
  1. 2.1 Daptomycin API Industry Trends
  2. 2.2 Daptomycin API Industry Drivers
  3. 2.3 Daptomycin API Industry Opportunities and Challenges
  4. 2.4 Daptomycin API Industry Restraints
3 Daptomycin API Market by Company
  1. 3.1 Global Daptomycin API Company Revenue Ranking in 2025
  2. 3.2 Global Daptomycin API Revenue by Company (2021-2026)
  3. 3.3 Global Daptomycin API Sales Volume by Company (2021-2026)
  4. 3.4 Global Daptomycin API Average Price by Company (2021-2026)
  5. 3.5 Global Daptomycin API Company Ranking (2024-2026)
  6. 3.6 Global Daptomycin API Company Manufacturing Base and Headquarters
  7. 3.7 Global Daptomycin API Company Product Type and Application
  8. 3.8 Global Daptomycin API Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Daptomycin API Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Daptomycin API Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Daptomycin API Market by Type
  1. 4.1 Daptomycin API Type Introduction
  2. 4.1.1 0.99
  3. 4.1.2 0.98
  4. 4.1.3 Others
  5. 4.2 Global Daptomycin API Sales Volume by Type
  6. 4.2.1 Global Daptomycin API Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Daptomycin API Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Daptomycin API Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Daptomycin API Sales Value by Type
  10. 4.3.1 Global Daptomycin API Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Daptomycin API Sales Value by Type (2021-2032)
  12. 4.3.3 Global Daptomycin API Sales Value Share by Type (2021-2032)
5 Daptomycin API Market by Application
  1. 5.1 Daptomycin API Application Introduction
  2. 5.1.1 350mg/vial
  3. 5.1.2 500mg/vial
  4. 5.1.3 Others
  5. 5.2 Global Daptomycin API Sales Volume by Application
  6. 5.2.1 Global Daptomycin API Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Daptomycin API Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Daptomycin API Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Daptomycin API Sales Value by Application
  10. 5.3.1 Global Daptomycin API Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Daptomycin API Sales Value by Application (2021-2032)
  12. 5.3.3 Global Daptomycin API Sales Value Share by Application (2021-2032)
6 Daptomycin API Regional Sales and Value Analysis
  1. 6.1 Global Daptomycin API Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Daptomycin API Sales by Region (2021-2032)
  3. 6.2.1 Global Daptomycin API Sales by Region: 2021-2026
  4. 6.2.2 Global Daptomycin API Sales by Region (2027-2032)
  5. 6.3 Global Daptomycin API Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Daptomycin API Sales Value by Region (2021-2032)
  7. 6.4.1 Global Daptomycin API Sales Value by Region: 2021-2026
  8. 6.4.2 Global Daptomycin API Sales Value by Region (2027-2032)
  9. 6.5 Global Daptomycin API Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Daptomycin API Sales Value (2021-2032)
  12. 6.6.2 North America Daptomycin API Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Daptomycin API Sales Value (2021-2032)
  15. 6.7.2 Europe Daptomycin API Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Daptomycin API Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Daptomycin API Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Daptomycin API Sales Value (2021-2032)
  21. 6.9.2 South America Daptomycin API Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Daptomycin API Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Daptomycin API Sales Value Share by Country, 2025 VS 2032
7 Daptomycin API Country-level Sales and Value Analysis
  1. 7.1 Global Daptomycin API Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Daptomycin API Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Daptomycin API Sales by Country (2021-2032)
  4. 7.3.1 Global Daptomycin API Sales by Country (2021-2026)
  5. 7.3.2 Global Daptomycin API Sales by Country (2027-2032)
  6. 7.4 Global Daptomycin API Sales Value by Country (2021-2032)
  7. 7.4.1 Global Daptomycin API Sales Value by Country (2021-2026)
  8. 7.4.2 Global Daptomycin API Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Daptomycin API Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Daptomycin API Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Daptomycin API Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Daptomycin API Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Daptomycin API Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Daptomycin API Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Daptomycin API Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Daptomycin API Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Daptomycin API Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Daptomycin API Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Daptomycin API Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Daptomycin API Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Daptomycin API Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Daptomycin API Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Daptomycin API Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Daptomycin API Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Daptomycin API Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Daptomycin API Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Daptomycin API Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Daptomycin API Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Daptomycin API Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Daptomycin API Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Daptomycin API Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Daptomycin API Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Daptomycin API Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Daptomycin API Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Daptomycin API Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Daptomycin API Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Daptomycin API Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Daptomycin API Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Daptomycin API Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Daptomycin API Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Daptomycin API Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Daptomycin API Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Daptomycin API Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Daptomycin API Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Daptomycin API Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Daptomycin API Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Daptomycin API Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Daptomycin API Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Daptomycin API Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Daptomycin API Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Daptomycin API Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Daptomycin API Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Daptomycin API Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Daptomycin API Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Daptomycin API Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Daptomycin API Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Daptomycin API Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Daptomycin API Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Daptomycin API Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Daptomycin API Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Daptomycin API Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Daptomycin API Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Daptomycin API Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Daptomycin API Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Daptomycin API Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Daptomycin API Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Daptomycin API Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Daptomycin API Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Daptomycin API Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Daptomycin API Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Daptomycin API Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Daptomycin API Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Daptomycin API Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Daptomycin API Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Daptomycin API Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Daptomycin API Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Daptomycin API Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Daptomycin API Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Daptomycin API Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Daptomycin API Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Daptomycin API Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Daptomycin API Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Daptomycin API Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Daptomycin API Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Daptomycin API Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Daptomycin API Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Daptomycin API Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Daptomycin API Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Daptomycin API Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Daptomycin API Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Daptomycin API Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Daptomycin API Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chongqing DaXin Pharmaceutical Co
  2. 8.1.1 Chongqing DaXin Pharmaceutical Co Company Information
  3. 8.1.2 Chongqing DaXin Pharmaceutical Co Business Overview
  4. 8.1.3 Chongqing DaXin Pharmaceutical Co Daptomycin API Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chongqing DaXin Pharmaceutical Co Daptomycin API Product Portfolio
  6. 8.1.5 Chongqing DaXin Pharmaceutical Co Recent Developments
  7. 8.2 Suzhou Pharmaceutical Technology Co
  8. 8.2.1 Suzhou Pharmaceutical Technology Co Company Information
  9. 8.2.2 Suzhou Pharmaceutical Technology Co Business Overview
  10. 8.2.3 Suzhou Pharmaceutical Technology Co Daptomycin API Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Suzhou Pharmaceutical Technology Co Daptomycin API Product Portfolio
  12. 8.2.5 Suzhou Pharmaceutical Technology Co Recent Developments
  13. 8.3 Livzon Group Fuzhou Fuxing Pharmaceutical Co
  14. 8.3.1 Livzon Group Fuzhou Fuxing Pharmaceutical Co Company Information
  15. 8.3.2 Livzon Group Fuzhou Fuxing Pharmaceutical Co Business Overview
  16. 8.3.3 Livzon Group Fuzhou Fuxing Pharmaceutical Co Daptomycin API Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Livzon Group Fuzhou Fuxing Pharmaceutical Co Daptomycin API Product Portfolio
  18. 8.3.5 Livzon Group Fuzhou Fuxing Pharmaceutical Co Recent Developments
  19. 8.4 Huazhong Pharmaceutical Co
  20. 8.4.1 Huazhong Pharmaceutical Co Company Information
  21. 8.4.2 Huazhong Pharmaceutical Co Business Overview
  22. 8.4.3 Huazhong Pharmaceutical Co Daptomycin API Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Huazhong Pharmaceutical Co Daptomycin API Product Portfolio
  24. 8.4.5 Huazhong Pharmaceutical Co Recent Developments
  25. 8.5 Xellia Pharmaceuticals
  26. 8.5.1 Xellia Pharmaceuticals Company Information
  27. 8.5.2 Xellia Pharmaceuticals Business Overview
  28. 8.5.3 Xellia Pharmaceuticals Daptomycin API Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Xellia Pharmaceuticals Daptomycin API Product Portfolio
  30. 8.5.5 Xellia Pharmaceuticals Recent Developments
  31. 8.6 Tecoland Corporation
  32. 8.6.1 Tecoland Corporation Company Information
  33. 8.6.2 Tecoland Corporation Business Overview
  34. 8.6.3 Tecoland Corporation Daptomycin API Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Tecoland Corporation Daptomycin API Product Portfolio
  36. 8.6.5 Tecoland Corporation Recent Developments
  37. 8.7 Rochem International Inc
  38. 8.7.1 Rochem International Inc Company Information
  39. 8.7.2 Rochem International Inc Business Overview
  40. 8.7.3 Rochem International Inc Daptomycin API Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Rochem International Inc Daptomycin API Product Portfolio
  42. 8.7.5 Rochem International Inc Recent Developments
  43. 8.8 Athos
  44. 8.8.1 Athos Company Information
  45. 8.8.2 Athos Business Overview
  46. 8.8.3 Athos Daptomycin API Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Athos Daptomycin API Product Portfolio
  48. 8.8.5 Athos Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Daptomycin API Value Chain Analysis
  2. 9.1.1 Daptomycin API Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Daptomycin API Sales Mode & Process
  6. 9.2 Daptomycin API Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Daptomycin API Distributors
  9. 9.2.3 Daptomycin API Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst